Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Who will pay the price for inaction on superbugs?While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts Share XWho will pay the price for inaction on superbugs?https://pharmaphorum.com/r-d/views-analysis-r-d/who-will-pay-the-price-for-inaction-on-superbugs/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
Achieving launch excellence in orphan medicinesNew rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking Share XAchieving launch excellence in orphan medicineshttps://pharmaphorum.com/market-access-2/achieving-launch-excellence-in-orphan-medicines/
Optimising market access for biosimilarsWe speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for Share XOptimising market access for biosimilarshttps://pharmaphorum.com/views-analysis-market-access/optimising-market-access-for-biosimilars/
It’s good to talk, NICE says to pharma industry groupNICE has entered into a new dialogue with industry to highlight the benefits of its early scientific advice Share XIt’s good to talk, NICE says to pharma industry grouphttps://pharmaphorum.com/views-analysis-market-access/its-good-to-talk-nice-says-to-pharma-industry-group/
Nine for 2019: Opportunities for pharmaIn the last Nine for 2019 article, we reflected on the major challenges that are shaping the pharmaceutical Share XNine for 2019: Opportunities for pharmahttps://pharmaphorum.com/views-and-analysis/nine-for-2019-opportunities-for-pharma/
Nine for 2019: Challenges impacting pharmaAs we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping Share XNine for 2019: Challenges impacting pharmahttps://pharmaphorum.com/r-d/views-analysis-r-d/nine-for-2019-challenges-impacting-pharma/
Gene therapy and market access: the pharmaphorum podcastFor episode 10 of the pharmaphorum podcast I spoke to Nicola Redfern, who’s general manager at bluebird bio Share XGene therapy and market access: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gene-therapy-market-access
